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Abstract
Aims/hypothesis Women with diabetes remain at increased risk of adverse pregnancy outcomes associated with poor pregnancy
preparation. However, women with type 2 diabetes are less aware of and less likely to access pre-pregnancy care (PPC) compared
with women with type 1 diabetes. We developed and evaluated a community-based PPC programme with the aim of improving
pregnancy preparation in all women with pregestational diabetes.
Methods This was a prospective cohort study comparing pregnancy preparation measures before and during/after the PPC
intervention in women with pre-existing diabetes from 1 June 2013 to 28 February 2017. The setting was 422 primary
care practices and ten National Health Service specialist antenatal diabetes clinics. A multifaceted approach was taken to
engage women with diabetes and community healthcare teams. This included identifying and sending PPC information
leaflets to all eligible women, electronic preconception care templates, online education modules and resources, and
regional meetings and educational events. Key outcomes were preconception folic acid supplementation, maternal
HbA1c level, use of potentially harmful medications at conception and gestational age at first presentation, before and
during/after the PPC programme.
Results A total of 306 (73%) primary care practices actively participated in the PPC programme. Primary care
databases were used to identify 5075 women with diabetes aged 18–45 years. PPC leaflets were provided to 4558
(89.8%) eligible women. There were 842 consecutive pregnancies in women with diabetes: 502 before and 340
during/after the PPC intervention. During/after the PPC intervention, pregnant women with type 2 diabetes were
more likely to achieve target HbA1c levels ≤48 mmol/mol (6.5%) (44.4% of women before vs 58.5% of women
during/after PPC intervention; p = 0.016) and to take 5 mg folic acid daily (23.5% and 41.8%; p = 0.001). There was
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an almost threefold improvement in ‘optimal’ pregnancy preparation in women with type 2 diabetes (5.8% and
15.1%; p = 0.021). Women with type 1 diabetes presented for earlier antenatal care during/after PPC (54.0% vs
67.3% before 8 weeks’ gestation; p = 0.003) with no other changes.
Conclusions/interpretation A pragmatic community-based PPC programme was associated with clinically relevant improve-
ments in pregnancy preparation in women with type 2 diabetes. To our knowledge, this is the first community-based PPC
intervention to improve pregnancy preparation for women with type 2 diabetes.
Data availability Further details of the data collection methodology, individual clinic data and the full audit reports for healthcare
professionals and service users are available from https://digital.nhs.uk/data-and-information/clinical-audits-and-registries/our-
clinical-audits-and-registries/national-pregnancy-in-diabetes-audit.
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Abbreviations
CCG Clinical commissioning group
EAHSN Eastern Academic Health Science Network
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NICE National Institute for Health and Care Excellence
NPID National Pregnancy in Diabetes
PPC Pre-pregnancy care
Introduction
Women with pregestational diabetes remain at increased risk of
adverse pregnancy outcomes associated with suboptimal preg-
nancy preparation [1, 2]. A large national cohort in the UK
demonstrated that only 14% of women with type 1 diabetes
and 37% of women with type 2 diabetes achieve the National
Institute for Health and Care Excellence (NICE) guideline
HbA1c target of 48 mmol/mol (<6.5%) [3, 4]. Furthermore,
only 46% and 23% of women with type 1 and type 2 diabetes
•
•
•
•
•
•
•
•
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respectively, were taking 5 mg of folic acid daily prior to con-
ception [3]. This leaves much room for improvement.
Pre-pregnancy care (PPC) has been shown to improve
pregnancy preparation measures such as preconception folic
acid supplementation, periconception glycaemic control,
avoiding potentially harmful medications and presenting for
early antenatal care [5–7]. We previously demonstrated that
althoughwomenwith type 2 diabetes have additional obstetric
risk factors (higher age, parity, BMI) compared with women
who have type 1 diabetes, PPC is as effective in reducing the
risk of serious adverse pregnancy outcomes in type 2 as in
type 1 diabetes [5, 8]. Despite its well-established benefits and
widespread recommendation, PPC attendance continues to be
low [4–6, 9, 10]. Even in regions with specialist programmes,
only a third of women with type 2 diabetes attend PPC [5, 6].
Conversely, the use of contraception also continues to be low,
with less than half of women with type 1 and type 2 diabetes
on potentially harmful prescribed medications using safe, ef-
fective methods of contraception [11].
Most women with type 2 diabetes have routine care in
primary care settings, where awareness of the specific issues
of diabetes pregnancy preparation is limited [8, 12]. This leads
to low levels of awareness regarding the importance of safe,
effective contraception to avoid an unintended pregnancy and
of PPC in women who are thinking about trying for a baby.
Women with type 2 diabetes are more likely to live in areas of
socioeconomic deprivation and belong to ethnic minority
groups so may have additional financial, cultural and ethnic
barriers to accessing healthcare [8, 12].
Qualitative interviews suggested that women with type 2
diabetes had common misconceptions about their reproduc-
tive potential [13, 14], thinking it was ‘harder to conceive’
with poorly controlled diabetes and high BMI [13, 14].
Some overweight and obese women were advised that they
had ‘too many risk factors’ for hormonal contraception.
Others reported concerns regarding the negative views of
women with type 2 diabetes and pre-pregnancy discussions
[13, 15]. Information about diabetes pregnancy was seen as
too ‘risk-focused’ and ‘alarming’, concentrating on ‘all the
bad things that could happen’ [14].Women stated a preference
for clear practical advice about sex and diabetes with less
emphasis on ‘preconception and having a baby’ [14].
There is an unmet need to improve women’s and healthcare
professionals’ awareness about diabetes pregnancy risks and
how they can be minimised by optimal pregnancy preparation
[8]. To address this, we developed and implemented an inte-
grated community-based PPC programme for women with
pregestational diabetes (type 1, type 2 and other), focusing on
engaging primary care diabetes teams. This study assesses its
effectiveness on pregnancy preparation measures and pregnan-
cy outcomes in women with pre-existing diabetes. We
hypothesised that a community-based PPC programme would
improve pregnancy preparation in women with type 2 diabetes.
Methods
A multifaceted approach was taken to engage women with
diabetes (type 1, type 2 and other, including MODY) as well
as their primary healthcare providers, including primary care
practitioners and community healthcare teams in the Eastern
Academic Health Science Network (EAHSN) (see electronic
supplementary material [ESM] for details of participating clin-
ical commissioning groups [CCGs]). This included identifying
and sending theoretically guided (balancing the risk of unat-
tended pregnancy and benefits of pregnancy preparation) pa-
tient information leaflets to all eligible women (ESM Fig. 1),
providing preconception care templates for use during face-to-
face primary care visits (ESM Fig. 2), providing online PPC
education modules and resources, as well as participating in a
series of regional and local educational events for patients and
healthcare professionals. The NPID patient information leaflet
and consent form met the Health Research Authority require-
ments for clinical audit, and research ethics approval was not
required.
Pre-existing regional programme This community-based pro-
gramme was established in addition to the existing East
Anglia Study Group for Improving Pregnancy Outcomes in
Women with Diabetes (EASIPOD) programme [5, 8, 14].
EASIPOD was established in 2006 to improve specialist
PPC clinic attendance. It involved the mailing of leaflets to
women with diabetes by the specialist antenatal diabetes
teams, and dissemination of information to various healthcare
professionals. It was not community based and did not sys-
tematically include primary care practitioners.
PPC leaflet Primary care centre databases (SystmOne and
EMIS) were searched using specific Read codes (https://
digital.nhs.uk/article/1104/Read-Codes) to identify women
with diabetes aged 16–45 years. Women who were currently
pregnant, recently widowed, or who had had a previous
hysterectomy, serious medical and/or psychological problems
were excluded. The theoretically guided EASIPOD PPC infor-
mation leaflet was revised to reflect the feedback from women
who previously did not attend for PPC [14]. It was deliberately
as inclusive as possible, focusing more on sex and contracep-
tion with less emphasis on ‘trying for a baby’, which previous
research suggested was a potential barrier for hard-to-reach
women (ESM Fig. 1). Printed and electronic copies of the
revised PPC leaflet were distributed to 422 primary care centres
and ten specialist diabetes maternity clinics. A nominal pay-
ment of £20 was offered to participating primary care centres to
cover their administrative costs of identifying eligible women
and mailing the leaflet (database search, stationery, postage).
Electronic preconception care templates Preconception care
templates were embedded into electronic healthcare records,
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with pop-up alerts as an aide-memoire, to promote use during
clinical encounters (ESM Fig. 2). Women not using safe, ef-
fective contraception were advised to consider a long-acting
reversible contraception method. Women thinking about try-
ing for a baby were advised to take 5 mg folic acid daily, to
aim for HbA1c ≤48 mmol/mol (6.5%), have a review of their
current medications and their most recent renal, retinal and
thyroid screening results. Specific recommendations for refer-
ral to a specialist diabetes pre-pregnancy service were made
for women with HbA1c >53 mmol/mol (7%), BMI>30 kg/m
2
and women with additional medical or obstetric risk factors
(ESM Fig. 2).
Online resources An online diabetes education programme
(Cambridge Diabetes Education programme, www.cdep.org.
uk; accessed 1 October 2015) was offered, free of charge, to
all participating primary and specialist care practices. In
addition, practices were invited to participate in a pilot
evaluation of the Diabetes UK preconception information
prescription www.diabetes.org.uk/professionals/resources/
resources-to-improve-your-clinical-practice/information-
prescriptions-qa/information-prescription–diabetes-
contraception-and-pregnancy (accessed 1 May 2016).
Regional meetings A project midwife was supported by local
project coordinators (each working 1–2 days/week) in seven
CCG areas. The project coordinators directly engaged with
local CCG leads, family physicians, primary care nurses, spe-
cialist diabetes teams, sexual health clinics, community groups
and women with diabetes. Regional meetings were held every
4 months to review pregnancy preparation and pregnancy out-
come data both during the baseline data collection before PPC
programme implementation (June 2013 to September 2015;
28 months) and during/after implementation (October 2015 to
February 2017; 17 months). The project midwife, local coordi-
nators and members of the National Health Service specialist
diabetes pregnancy teams attended these meetings, which
allowed teams to share experiences about what PPC engage-
ment activities worked and/or did not work.
Project cost The total cost for this large regional programme
included non-recurring programme management and
organisational costs, as well as staff who also delivered several
other diabetes improvement programmes. We estimated that
to deliver this model in a general UK population of 750,000
individuals including 58,000 with diabetes, the service would
require recurring salary costs for a 0.25 whole-time equivalent
project manager (£9,589) and three 0.25 whole-time equiva-
lent diabetes educators / midwives (£28,767), as well as non-
recurring initial modest costs for materials development
(£5,000) and primary care database searches, stationery and
postage (£20 × 306 = £6,120). This brings the total estimated
intervention cost to £49,476 per annum.
Data collection Health care professionals at each specialist
National Health Service maternity unit completed standardised
National Pregnancy in Diabetes (NPID) web-based data entry
forms (http://content.digital.nhs.uk/media/15927/NPID-Data-
Collection-Form-v6/pdf/NPID_Data_Collection_Form_v6.
pdf) for every pregnant woman with pregestational diabetes
who delivered between 1 June 2013 and 28 February 2017.
All women provided written informed consent for NPID data
collection. The project midwife ensured timely data collection,
validation of the data and entry into the study database. When
necessary, the project coordinator contacted individual sites to
ensure completeness and accuracy of the data. The pregnancy
preparation and pregnancy outcome data were reviewed on a
centre-by-centre basis at the quarterly regional meetings.
Definitions and outcomesWe defined pre-existing diabetes as
diabetes that had been diagnosed before pregnancy and ex-
cludedwomenwho presented with diabetes during pregnancy.
The mother’s diabetes type was added to the NPID data col-
lection as a mandatory data item from 1 January 2015 and was
obtained by linking to the most recent relevant National
Diabetes Audit record. Prior to January 2015, the type of
diabetes was determined by the treating clinicians and manu-
ally entered into the NPID database. Where the diabetes type
entered on the NPID system was not known, National
Diabetes Audit linkage was also used in order to establish a
known diabetes type for asmanywomen as possible. All types
of pre-existing diabetes were included. The HbA1c was mea-
sured locally, with the first and last recorded values during
pregnancy collected as per the NPID audit [3]. Target HbA1c
was defined as ≤48 mmol/mol (6.5%) in accordance with
NICE guidelines [4]. Optimal pregnancy preparation was de-
fined as having all of the following: on 5 mg folic acid sup-
plementation, not taking any potentially harmful medications
prior to last menstrual period, first HbA1c following confirma-
tion of a positive pregnancy test ≤48 mmol/mol (6.5%) and
presentation for antenatal diabetes care before 8 weeks’ ges-
tation. Medications considered potentially harmful included
secretagogues, dipeptidyl peptidase-4 (DPP-4) inhibitors,
glucagon-like peptide-1 (GLP-1) agonists, thiazolidinediones,
angiotensin converting enzyme inhibitors, angiotensin recep-
tor blockers and statins.
We used standard NPID definitions for congenital anoma-
ly, stillbirth and neonatal death and collected data on congen-
ital anomalies for live births, stillbirths and pregnancy loss
after 20 weeks’ gestation. The reported diagnoses for major
congenital anomaly, as defined by the European Surveillance
of Congenital Anomalies (EUROCAT), were obtained from
the hospital ICD-10 codes (www.who.int/classifications/icd/
en/) [16]. All congenital anomaly coding was reviewed in
duplicate. Minor congenital anomalies were not included.
Infant birthweight was adjusted for maternal height,
weight, infant sex and gestational age using customised
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centile calculators (Gestation Related Optimal Weight
[GROW] centile tool v6.7.7.1 [UK] 2015 Gestation
Network) (www.gestation.net/birthweight_centiles/centile_
object.htm, accessed 8 November 2017).
Statistical analysis Differences before and during/after the im-
plementation of the programme were analysed using t tests for
continuous variables and Fisher’s exact test for categorical
variables after ensuring test assumptions were met. A two-
sided p value of <0.05 was considered statistically significant.
Analyses were performed using Stata, version 14.1.
Results
Primary care participation Out of 422 primary care centres
identified, 306 (72.5%) actively participated in the pro-
gramme. Collectively, they identified 5075 women with
pregestational diabetes aged 16–45 years, excluded 514 for
whom it was considered inappropriate, and sent the pre-
pregnancy information leaflet to the remaining 4,558
(89.8%) (Table 1). The primary care response rate exceeded
75% in five out of seven CCG areas. Details according to each
CCG area are shown in Table 1.
Login codes for the online diabetes education programme
(Cambridge Diabetes Education Programme) were created for
up to 1500 users. Of those, 311 individuals registered for the
programme. This included individuals from primary care
practices (182), hospitals (57) and other institutions such as
care homes, pharmacies, community trusts etc. (72). A total of
221 individuals started at least one module and 75 completed
at least one module during the 17 month PPC programme
implementation phase. The most popular completed modules
were: What is diabetes? (n = 63), Hypoglycaemia (n = 52),
Hyperglycaemia (n = 39), Screening and early detection of
type 2 diabetes (n = 36) and Preconception care (n = 32).
Specialist antenatal diabetes care participation Of the 842
women who presented with pregnancies complicated by dia-
betes, 513 (60.9%) had type 1 diabetes, 318 (37.8%) had type
2 diabetes and 11 (1.3%) had other types of diabetes in preg-
nancy. Specialist clinics varied by number of pregnancies in
women with pre-existing diabetes, which ranged from 32–173
women. A total of 502 women who attended before and 340
women who attended during/after the PPC programme were
included.
Maternal characteristics The proportion of women with type 1
and type 2 diabetes remained consistent over time (61.4%
before vs 60.3% with type 1 diabetes during/after the pro-
gramme; p = 0.77), as did maternal BMI at booking (29.3 ±
7.2 kg/m2 vs 29.8 ± 6.9 kg/m2; p = 0.29) (ESM Table 1).
Women who attended during/after the implementation of the
PPC programmewere younger (31.4 ± 5.9 vs 32.5 ± 5.9 years;
p = 0.0074). Details of maternal characteristics before and
during/after intervention are found in ESM Table 1.
Less than half of women with type 1 diabetes (41.0% be-
fore and 36.1% during/after PPC; p = 0.27) and approximately
one in ten with type 2 diabetes (12.4% before and 9.9%
during/after PPC; p = 0.59) had a BMI in the normal range
of <24.9 kg/m2. Details of maternal characteristics by type
of diabetes (type 1 or type 2) are shown in Table 2.
For women with type 1 diabetes, 23.1% and 22.4% used
insulin pump therapy before and during/after PPC respective-
ly, and 7.5% and 10.7% were taking metformin in early preg-
nancy before and during/after PPC respectively. For women
with type 2 diabetes, 72.0% and 69.7% respectively were
taking metformin in early pregnancy.
Pregnancy preparation Almost two-thirds (64.2–64.6%) of
women with type 1 diabetes were on folic acid before concep-
tion with very few (<4%) taking any potentially harmful med-
ications before and during/after PPC implementation
(Table 3). In women with type 1 diabetes, only gestational
Table 1 Women with diabetes identified and sent PPC leaflets by CCG areas
CCG area Primary care
practices contacted
Primary care
practice replies
Women with
diabetes identified
PPC leaflets
sent
Norfolk and Waveneya 110 83 (75.5%) 1438 1246
Cambridgeshire and Peterborough 107 81 (75.7%) 1289 1276
East and North Hertfordshire 59 46 (78%) 699 583
Ipswich and East Suffolk 40 35 (87.5%) 638 549
West Suffolk 25 24 (96.0%) 425 397
Bedfordshire 40 13 (32.5%) 199 176
North East Essex 41 24 (58.5%) 387 331
Total 422 306 (72.5%) 5075 4558 (89.8%)
aNorfolk and Waveney are comprised of the following CCGs: Norwich, North Norfolk, South Norfolk, West Norfolk, Great Yarmouth and Waveney
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age at booking (8.4 ± 3.5 vs 7.6 ± 3.7 weeks; p = 0.020) and
booking prior to 8 weeks’ gestation (54% vs 67.3%; p =
0.003) improved significantly (Table 3). There was a trend
towards increasing ‘optimal’ preparation for pregnancy, but
this did not reach statistical significance (10.6% vs 16.3%;
p = 0.086).
In contrast, women with type 2 diabetes were significantly
more likely to achieve a target HbA1c ≤48mmol/mol (6.5%)
(44.4% before vs 58.5% during/after PPC implementation;
p = 0.016) and to take preconception folic acid, both for ‘any
dose’ (36.6% before vs 48.9% during/after PPC implementa-
tion; p = 0.041) and for the NICE recommended 5 mg dose
Table 2 Maternal characteristics before and during/after implementation of a regional PPC programme by type of diabetes
Type 1 diabetes Type 2 diabetes
Characteristic Before PPC During/after PPC p value Before PPC During/after PPC p value
n=308 n=205 n=186 n=132
Age in years at delivery, mean (SD) 31.2 (5.9) 30.2 (5.8) 0.058 34.7 (5.2) 33.4 (5.4) 0.026
Diabetes treatment at first visit, n (%)
Insulin pump 71 (23.1) 46 (22.4) 0.92 0 (0) 0 (0) –
Metformin 23 (7.5) 22 (10.7) 0.21 134 (72.0) 92 (69.7) 0.71
Weight at booking in kg, mean (SD)a 71.8 (13.8) 74.2 (15.2) 0.068 91.2 (24.5) 90.8 (21.5) 0.87
BMI at booking in kg/m2, mean (SD) 26.5 (4.6) 27.3 (5.3) 0.068 34.3 (8.0) 33.9 (7.2) 0.71
Normal (<24.9) 126 (41.0) 74 (36.1) 0.27 23 (12.4) 13 (9.9) 0.59
Overweight (25–29.9) 125 (40.7) 75 (36.6) 0.36 31 (16.7) 28 (21.2) 0.31
Obese (≥30) 56 (18.2) 56 (27.3) 0.017 132 (71.0) 91 (68.9) 0.71
aMaternal weight at booking was available for all but one participant with type 1 diabetes before PPC
Table 3 Measures of pregnancy preparation before and during/after implementation of a regional PPC programme by type of diabetes
Type 1 diabetes Type 2 diabetes
Measure Before PPC During/after PPC p value Before PPC During/after PPC p value
n=308a n=205a n=186a n=132a
Booking time n = 304 n = 205 n = 185 n = 132
Gestational age at booking in weeks, mean (SD) 8.4 (3.5) 7.6 (3.7) 0.020 10.5 (4.5) 9.8 (4.9) 0.25
Booking prior to 8 weeks, n (%) 164 (54.0) 138 (67.3) 0.003 62 (33.5) 53 (40.2) 0.24
HbA1c n = 287 n = 198 n = 178 n = 130
HbA1c at first contact in mmol/mol, mean (SD) 62.2 (18.3) 61.5 (17.3) 0.65 52.2 (14.9) 50.4 (14.8) 0.30
HbA1c at first contact in %, mean (SD) 7.8 (3.8) 7.8 (3.7) 0.65 6.9 (3.5) 6.8 (3.5) 0.30
First HbA1c ≤48mmol/mol, n (%) 62 (21.6) 46 (23.2) 0.74 79 (44.4) 76 (58.5) 0.016
Preconception folic acid n = 288 n = 195 n = 164 n = 123
Preconception folic acid any dose, n (%) 185 (64.2) 126 (64.6) 1.00 60 (36.6) 60 (48.9) 0.041
Preconception folic acid 5 mg dose dailyb, n (%) 174 (60.6) 113 (58.0) 0.57 38 (23.5) 51 (41.8) 0.001
Potentially harmful medication n = 274 n = 204 n = 169 n = 131
On at least one potentially harmful medicationc, n (%) 10 (3.7) 3 (1.5) 0.17 27 (16.0) 16 (12.2) 0.41
Two or more potentially harmful medications, n (%) 0 (0) 0 (0) – 7 (4.1) 2 (1.5) 0.31
Optimal pregnancy preparationd 0.086 0.021
n n = 236 n = 190 n = 138 n = 119
n (%) 25 (10.6) 31 (16.3) 8 (5.8) 18 (15.1)
a n values are shown below for the number of participants for which these data were available for each category of measures or each individual measure
b n values for numbers of participants with data for 5 mg daily dose of folic acid are 287 (type 1 diabetes before PPC); 195 (type 1 diabetes during/after
PPC); 162 (type 2 diabetes before PPC); 122 (type 2 diabetes during/after PPC)
c Potentially harmful medications include secretagogues, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) agonists,
thiazolidinedione, angiotensin converting enzyme inhibitor / angiotensin receptor blockers and statin
d Optimal pregnancy preparation defined as first HbA1c ≤48 mmol/mol (6.5%), on folic acid 5mg daily prior to last menstrual period, booking at ≤8
weeks gestation and no harmful medications prior to last menstrual period
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(23.5% before and 41.8% during/after PPC implementation;
p = 0.001). There was almost a threefold improvement in ‘op-
timal’ pregnancy preparation during/after PPC implementa-
tion in women with type 2 diabetes (5.8% before and 15.1%
during/after PPC implementation; p = 0.021) (Table 3).
Overall, 16% of women with pregestational diabetes were
considered ‘optimally’ prepared for pregnancy during/after
implementation (ESM Table 2). There was no change in the
proportion of women with type 2 diabetes taking potentially
harmful medications (16% before and 12.2% during/after PPC
implementation; p = 0.41).
Pregnancy outcomes Pregnancy outcomes for the 812 single-
ton pregnancies of women with type 1 and type 2 diabetes are
shown in Table 4. There were five perinatal deaths in type 1
diabetes pregnancies before (three stillbirths and two neonatal
deaths) and none during/after PPC implementation. However,
there were more congenital anomalies in type 1 diabetes off-
spring during/after PPC implementation, meaning that the over-
all rate of serious adverse pregnancy outcome was unchanged.
There were no differences in most perinatal morbidity out-
comes before and during/after PPC implementation. There
was evidence for an overall increase in neonatal intensive care
unit admissions (40.4% before vs 48.9% during/after PPC
implementation; p = 0.022), which is likely due to a trend
towards earlier obstetric intervention (29.7% vs 36.1% pre-
term delivery <37 weeks gestation; p = 0.071) (ESM
Table 3). This was driven mainly by a higher proportion of
type 1 diabetes neonates requiring advanced neonatal care
(46.6% before vs 56.7% during/after PPC implementation;
p = 0.022) (Table 4).
Discussion
We report on a pragmatic community-based PPC programme
that is simple and effective in improving pregnancy prepara-
tion in women with type 2 diabetes. Almost 75% of primary
care centres were actively engaged in identifying women with
diabetes and sending them information about sex, contracep-
tion and pregnancy. Significant improvements in pregnancy
preparation were seen in women with type 2 diabetes with
almost 60% reaching target HbA1c at conception, and 50%
taking preconception folic acid. Although most women
(85%) with type 2 diabetes were not optimally prepared for
pregnancy, there was an overall threefold improvement in
pregnancy preparation measures. Women with type 1 diabetes
had higher than average rates of folic acid supplementation
before and during/after with the only significant difference
being earlier presentation for antenatal care during and after
implementation of the PPC programme.
This community-based PPC programme was developed to
address the limitations of a previous regional programmewhich
was effective for improving pregnancy outcomes but was fo-
cused on specialist pre-pregnancy clinics and did not adequate-
ly engage with primary care teams [5]. With a 90% increase in
type 2 diabetes over 15 years and increasing numbers of youn-
ger women with type 2 diabetes, primary care practitioners
(nurses and family physicians) are increasingly providing rou-
tine diabetes care [17]. This programme was primarily focused
on raising awareness about the importance of safe, effective
contraception and/or PPC among primary care teams.
Measures such as improvement in folic acid preparation
associatedwith the previous PPC programme have beenmain-
tained over the decade since it was first introduced [5].
Specifically, 46% and 33% of women with type 1 and type
2 diabetes were on preconception folic acid between 2006 and
2009, compared with 64% and 37% respectively prior to the
current intervention [5]. Thus, there had been ongoing im-
provements over time in type 1 diabetes but little or no change
in type 2 diabetes pregnancy. This programme demonstrated
clinically relevant improvements in type 2 diabetes pregnancy
with 49% of women with type 2 diabetes now taking precon-
ception folic acid.
Using the same definitions and data collection procedures
allows us to directly compare our findings with the NPID
audit of women with pregestational diabetes in England and
Wales. Only 15% and 38% of women with type 1 and type 2
diabetes in NPID achieved first trimester HbA1c <48mmol/
mol (6.5%) [18]. In our study, 23% and 58% of women with
type 1 and type 2 diabetes, respectively, achievedNICE guide-
line HbA1c targets during the PPC programme. Similar im-
provements were seen with 5 mg daily folic acid supplemen-
tation, with 42% and 23% of women with type 1 and type 2
diabetes in NPID, compared with 58% and 42%, respectively,
during our study. This is almost double the national rates for
pre-pregnancy folic acid supplementation in type 2 diabetes
pregnancy. Finally, only one in 12 women nationally were
considered well prepared for pregnancy (defined as HbA1c
<48mmol/mol (6.5%), 5 mg folic acid daily and no harmful
medications). In our study, one in seven women with pre-
existing diabetes were considered optimally prepared for preg-
nancy, which included a more stringent criterion of booking
before 8 weeks’ gestation.
In our study, more substantial improvements in pregnancy
preparation were observed in type 2 diabetes compared with
type 1 diabetes. There may be many reasons for this differ-
ence. First, our programme targeted primary care practitioners
and community healthcare teams, which would have had a
bigger impact on women with type 2 diabetes who are more
likely to receive their care in a community setting [8]. Second,
women with type 2 diabetes tend to have a shorter duration of
diabetes and a less severe glycaemic disturbance. They can be
treated more effectively with oral agents and are more likely to
reach target HbA1c than women with type 1 diabetes. Finally,
women with type 2 diabetes are more likely to be prescribed
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medications for hypertension and lipid lowering, offering an
achievable target for improvement in overall pregnancy prep-
aration [8].
In contrast, in women with type 1 diabetes, the rates of folic
acid supplementation and early presentation for antenatal care
compared favourably to national data, but optimising
glycaemic control remains a major hurdle. The recent
randomised controlled trial of continuous glucose monitoring
(CONCEPTT) highlighted that even with high rates of con-
tinuous glucose monitoring and insulin pump use, only about
Table 4 Pregnancy outcomes before and during/after implementation of PPC programme by type of diabetes
Type 1 diabetes Type 2 diabetes
Before PPC During/after PPC p value Before PPC During/after PPC p value
n=302a n=202a n=183a n=131a
Pregnancy outcomeb n = 302 n = 202 n = 183 n = 131
Live birth, n (%) 278 (92.1) 187 (92.6) 0.87 172 (94.0) 123 (93.9) 1.00
Miscarriage, n (%) 18 (6.0) 14 (6.9) 0.71 8 (4.4) 5 (3.8) 1.00
Termination, n (%) 3 (1.0) 1 (0.5) 0.65 2 (1.1) 0 (0) 0.51
Deliveryc n = 277 n = 187 n = 169 n = 126
Gestational age at delivery, mean (SD) 36.8 (2.2) 36.9 (1.7) 0.90 37.4 (1.9) 37.3 (1.75) 0.49
Prematurity
<37 weeks, n (%) 98 (35.4) 79 (42.3) 0.15 35 (20.7) 35 (27.8) 0.17
<34 weeks, n (%) 26 (9.4) 12 (6.4) 0.30 8 (4.7) 4 (3.2) 0.57
Birthweight (g) 0.43 0.85
n n = 280 n = 185 n = 173 n = 126
mean (SD) 3379.7 (700.0) 3429.6 (618.5) 3235.2 (665.5) 3249.7 (655.1)
Infant birth centilesd n = 275 n = 185 n = 169 n = 126
Large for gestational age, n (%) 121 (44.0) 86 (46.5) 0.63 32 (18.9) 28 (22.2) 0.56
Extremely large for gestational age, n (%) 80 (29.1) 59 (31.9) 0.54 17 (10.1) 14 (11.1) 0.84
Small for gestational age, n (%) 15 (5.5) 8 (4.3) 0.67 29 (17.2) 14 (11.1) 0.18
Advanced neonatal care 0.037 0.21
n n = 277 n = 187 n = 172 n = 123
n (%) 129 (46.6) 106 (56.7) 53 (30.8) 47 (38.2)
Other pregnancy outcomes
Congenital malformation 0.084 0.72
n n = 267 n = 177 n = 168 n = 121
n (%) 10 (3.8) 14 (7.9) 4 (2.4) 4 (3.3)
Stillbirth 0.28 0.31
n n = 281 n = 187 n = 173 n = 126
n (%) 3 (1.1) 0 (0) 1 (0.6) 3 (2.4)
Neonatal death 0.52 1.00
n n = 269 n = 176 n = 166 n = 112
n (%) 2 (0.74) 0 (0) 1 (0.6) 0 (0)
Perinatal mortality 0.16 0.40
n n = 272 n = 176 n = 167 n = 115
n (%) 5 (1.8) 0 (0) 2 (1.2) 3 (2.6)
n = 259 n = 171 n = 163 n = 113
Serious adverse outcomee, n (%) 14 (5.4) 14 (8.2) 0.32 6 (3.7) 7 (6.2) 0.39
a n values are shown for the number of participants for which these data were available for each category of measures or each individual measure
b Reported on all singleton pregnancies
c Reported on live and stillbirths
d Large for gestational age >90th centile, extremely large for gestational age >97.7th centile, small for gestational age <10th centile as per GROW
customised centiles
e Serious adverse outcome: malformation with or without termination of pregnancy, stillbirth or neonatal death
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50% of women attending specialist PPC clinics were able to
attain target HbA1c levels [19]. It also described a high pro-
portion (60%) of women with type 1 diabetes who were over-
weight and obese before pregnancy. Our data suggested an
increase in body weight and maternal BMI, even over the
course of the programme, with an average 2.4 kg and 0.8
BMI point increase, even though women were entering preg-
nancy at a younger age. Interestingly, there were no such
changes in women with type 2 diabetes. There is an unmet
need to develop evidence-based dietary advice and weight-
management guidelines for women with type 1 and type 2
diabetes.
While overall pregnancy preparation improved after the
implementation of our programme, 84% of women with
pregestational diabetes are still not ‘optimally’ prepared for
pregnancy. This highlights that much more needs to be done.
If the programme had been continued for a longer period,
more women may have benefitted. Ideally it would be imple-
mented over at least 12–24 months, to allow for maximum
participation before assessing its impact. Improvements in the
use of safe, effective contraception and in folic acid supple-
mentation for women not using appropriate contraception
should be prioritised in primary care. Also, further improve-
ments would be achieved if women with type 2 diabetes and
healthcare teams were more aware of the importance of im-
mediate referral for antenatal care following confirmation of
pregnancy. In specialist care, more attention is required in
helping women optimise glycaemic control.
Our study has some important strengths. We describe an
intervention that was simple, inexpensive, sustainable and
easily reproducible in other regions. It was performed over a
short time (only 17 months), with no substantial changes to
clinical practice guidelines and/or diabetes technology use and
no documented changes in national pregnancy preparation as
recorded by the same NPIDmeasures from 2014 to 2016 [18].
Thus, the improvements seen with the initiation of our pro-
gramme are unlikely related to wider changes in the care of
women with diabetes. We were able to demonstrate a benefit
of this programme despite the existing regional programme
and above average baseline measures of pregnancy prepara-
tion compared with NPID. Finally, it was simple to establish
and was achieved at a very modest cost of less than £50,000
per year. The 2014 National Reference Costs for the lifetime
specialist health care costs for each congenital anomaly were
estimated as £668,098 for neural tube defects, £434,340 for
cardiac malformations, £82,972 for gastrointestinal defects
and £47,160 for cleft lip and palate (personal communication,
P. King, Royal Derby Hospitals NHS Foundation Trust,
Derby, UK), suggesting that prevention of one cleft lip and
palate would cover the programme costs.
However, our study also has limitations. Because our pro-
grammewas multifaceted, we are unable to comment on which
component of the programme was most effective. We
hypothesise that the systematic provision of information to all
women with diabetes, the face-to-face contact with primary
care teams and the electronic preconception care templates
are all relevant. The uptake of other aspects such as the specific
preconception care module of the online education programme
was disappointing. Our study was likely not large enough or of
long-enough duration to detect differences in pregnancy out-
comes which would have required 580 pregnancies in the
follow-up period to detect 30% reduction in serious adverse
outcomes [5]. Unfortunately, the limited funding arrangements
did not allow a longer duration of follow up. Because we com-
pare the programme before and during/after, we are unable to
comment on overall rates of PPC attendance and their relation
to pregnancy outcomes. However, this is a pragmatic approach
to assessing the programme’s effectiveness. Furthermore, we
are not confounded by potential differences in women who
may and may not seek PPC. We lack information on other
important confounders including diabetes duration, smoking
and social disadvantage.
PPC remains an area of diabetes care in which measurable
improvements are achievable. We must continue to develop
and implement strategies such as electronic preconception
care templates that improve the uptake of safe, effective
methods of contraception and/or access to PPC for all women
with diabetes. The suboptimal glycaemic control and rising
rates of obesity in type 1 diabetes also require attention.
These types of programmes should be funded, implemented
and studied in additional settings and populations.
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